| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 754 | 831 | 871 | 823 | 819 | 1,299 | 795 | 803 | 707 | 888 | 834 | 785 | 764 | 964 | 838 | 2,132 | 776 | 939 | 826 | 826 | 815 | 985 | 833 | 962 | 850 | 1,050 | 985 | 1,015 | 849 | 1,016 |
| Expenses | 608 | 663 | 688 | 588 | 623 | 688 | 1,408 | 602 | 535 | 739 | 611 | 707 | 586 | 678 | 636 | 634 | 596 | 660 | 585 | 618 | 618 | 668 | 751 | 673 | 584 | 689 | 658 | 641 | 554 | 644 |
| EBITDA | 145 | 168 | 183 | 236 | 196 | 611 | -613 | 201 | 172 | 150 | 223 | 78 | 178 | 286 | 202 | 1,497 | 180 | 279 | 241 | 208 | 198 | 318 | 83 | 290 | 266 | 361 | 327 | 374 | 295 | 372 |
| Operating Profit % | 17 % | 19 % | 17 % | 22 % | 21 % | 22 % | -81 % | 22 % | 18 % | 16 % | 23 % | 5 % | 18 % | 27 % | 22 % | 22 % | 20 % | 28 % | 27 % | 22 % | 19 % | 30 % | 7 % | 28 % | 28 % | 32 % | 31 % | 34 % | 31 % | 34 % |
| Depreciation | 11 | 12 | 12 | 14 | 19 | 23 | 18 | 23 | 22 | 22 | 18 | 18 | 18 | 17 | 18 | 15 | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit Before Tax | 134 | 157 | 171 | 222 | 176 | 587 | -634 | 177 | 149 | 127 | 204 | 60 | 160 | 268 | 184 | 1,482 | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 |
| Tax | 50 | 56 | 57 | 75 | 63 | 85 | 27 | 39 | 38 | 51 | 48 | 45 | 39 | 64 | 34 | 263 | 44 | 69 | 60 | 57 | 49 | 82 | 20 | 76 | 67 | 91 | 78 | 96 | 74 | 97 |
| Net Profit | 84 | 101 | 114 | 147 | 114 | 503 | -661 | 138 | 111 | 77 | 157 | 14 | 121 | 204 | 150 | 1,219 | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 195 | 182 | 253 | 230 | 263 | 205 | 258 |
| EPS in ₹ | 9.93 | 5.95 | 6.71 | 8.67 | 6.70 | 29.68 | -39.03 | 8.15 | 6.54 | 4.51 | 10.26 | 0.85 | 7.14 | 12.06 | 8.87 | 71.96 | 7.04 | 11.42 | 9.71 | 7.41 | 7.04 | 12.84 | 9.89 | 11.37 | 10.76 | 14.67 | 13.57 | 15.52 | 12.10 | 15.07 |
GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals
2,505.00
-4.00
(-0.16%)
Key Fundamentals
Market Cap
42,436.21 Cr
EPS
54.76
PE Ratio
44.49
Dividend Yield
2.15 %
Industry
Healthcare 52 Week High
3,515.70
52 Week Low
1,921.00
PB Ratio
24.89
Debt to Equity
0.01
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
GlaxoSmithKline Pharmaceuticals Limited announced that Juby Chandy will assume the position of Vice President, Finance Asia Pacific (APAC) region effective December 1, 2025. Chandy will continue serving as Chief Financial Officer until a successor is appointed while providing strategic leadership to finance functions across Asia Pacific markets.
GlaxoSmithKline Pharmaceuticals Limited reported quarterly results with sales of ₹974 crores, representing a 2.6% decline. The company faced headwinds from a fire incident at a key contract manufacturing organization (CMO) impacting approximately ₹40 crores in revenue, and transitionary GST reform effects of ₹30-32 crores. Despite revenue challenges, EBITDA margins improved to 34.4%, a 250 basis point increase, driven by cost savings and better product mix. The company launched its oncology business on August 15, 2025, introducing Jemperli for endometrial cancer and Zejula for ovarian cancer. Vaccines business showed strong double-digit growth, while specialty products Nucala and Trelegy grew over 20%. The company maintains market share at 27.6% and reported EPS of ₹15.06, a 3% improvement. Management indicated the CMO fire impact and GST issues are resolved, with supply constraints expected to be behind them from Q3 onwards. GSK India is approaching its 102nd year of operations.
GlaxoSmithKline Pharmaceuticals Limited reported revenue from operations of Rs 97,994 lakhs for the quarter ended September 30, 2025, compared to Rs 101,077 lakhs in the same quarter last year, marking a decline of approximately 3%. For the six-month period, revenue dropped to Rs 178,511 lakhs from Rs 182,542 lakhs year-over-year. Net profit after tax increased to Rs 25,500 lakhs for the quarter versus Rs 23,640 lakhs in the previous year. The company's Board approved an investment of Rs 1.74 crores for a Solar Power project at its Nashik plant under Group Captive mechanism. This involves acquiring a 26% shareholding in CleanMax Galapagos Private Limited, a special purpose vehicle set up to supply 4.95 MWp capacity renewable energy. The company reported exceptional items credit of Rs 264 lakhs from profit on sale of surplus residential properties. Basic and diluted earnings per share for the quarter stood at Rs 18.06 compared to Rs 27.14 in the corresponding quarter last year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,777.20 | #1 4,26,409.81 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 71.49 | |
6,416.50 | 1,70,337.91 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 47.34 | |
3,699.40 | 1,25,204.51 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.89 | |
1,517.30 | 1,22,560.53 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.01 | |
1,240.40 | 1,03,525.49 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.56 | |
922.00 | 92,774.77 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 33.23 | |
2,022.20 | 92,364.90 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 58.77 | |
2,210.50 | 91,240.26 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.96 | |
1,201.20 | 69,765.89 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 63.26 | |
5,645.00 | 67,494.44 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 60.35 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
8.91 %
Net Income Growth
57.22 %
Cash Flow Change
121.62 %
ROE
43.24 %
ROCE
42.20 %
EBITDA Margin (Avg.)
17.79 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Fixed Assets | 123 | 210 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 |
| Current Assets | 2,587 | 2,174 | 1,674 | 2,186 | 2,010 | 1,775 | 2,203 | 3,708 | 2,494 | 2,798 | 3,410 |
| Capital Work in Progress | 115 | 268 | 606 | 923 | 1,003 | 120 | 13 | 31 | 20 | 14 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Current Liabilities | 1,107 | 579 | 720 | 1,600 | 1,454 | 1,024 | 1,355 | 1,698 | 1,326 | 1,525 | 1,905 |
| Non Current Liabilities | 280 | 292 | 277 | 290 | 317 | 291 | 282 | 272 | 259 | 254 | 252 |
| Total Equity | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,478 | 2,663 | 1,741 | 1,778 | 1,951 |
| Reserve & Surplus | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 |
| Share Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 |
| Investing Activities | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 |
| Operating Activities | 338 | 139 | 234 | 473 | 410 | 491 | 578 | 811 | 484 | 582 | 1,290 |
| Financing Activities | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.48 % | 4.02 % | 4.36 % | 4.50 % | 4.52 % | 4.89 % | 4.80 % |
| DIIs | 5.31 % | 5.51 % | 5.50 % | 5.61 % | 5.61 % | 4.08 % | 10.45 % | 10.28 % | 10.30 % | 10.23 % | 10.01 % | 8.53 % | 7.90 % | 7.50 % | 7.34 % | 7.30 % | 7.79 % | 7.70 % | 7.75 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 11.02 % | 10.86 % | 10.83 % | 10.67 % | 10.41 % | 10.41 % | 10.40 % | 10.56 % | 10.54 % | 10.57 % | 10.62 % | 11.08 % | 11.27 % | 11.15 % | 10.97 % | 10.96 % | 10.60 % | 10.32 % | 10.34 % |
| Others | 8.67 % | 8.62 % | 8.67 % | 8.73 % | 8.98 % | 10.51 % | 4.15 % | 4.16 % | 4.16 % | 4.20 % | 4.37 % | 5.38 % | 2.35 % | 2.33 % | 2.33 % | 2.23 % | 2.09 % | 2.09 % | 2.11 % |
| No of Share Holders | 1,19,951 | 1,20,476 | 1,21,445 | 1,23,480 | 1,10,141 | 1,12,964 | 1,16,651 | 1,20,127 | 1,20,415 | 1,19,032 | 1,15,266 | 1,14,663 | 1,18,994 | 1,18,515 | 1,19,228 | 1,19,625 | 1,21,885 | 1,23,629 | 1,22,904 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 30 | 35 | 20 | 40 | 30 | 90 | 32 | 32 | 54 |
| Dividend Yield (%) | 0.00 | 2.87 | 2.7 | 1.59 | 2.78 | 1.8 | 7.05 | 1.64 | 1.11 | 2.15 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Sept 2018 |  Bonus | 1:1 | 11 Sept 2018 | 1,726.60 | 1,724.70 |
| 20 Jul 2021 |  Dividend | ₹ 30.00 /share | 19 Jul 2021 | 1,518.15 | 1,607.55 |
| 08 Jul 2022 | Dividend | ₹ 60.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 08 Jul 2022 | Dividend | ₹ 30.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 26 Jul 2022 |  Annual General Meeting | NA | 26 Jul 2022 | 1,493.30 | 1,493.85 |
| 30 Jun 2023 | Dividend | ₹ 32.00 /share | 30 Jun 2023 | 1,289.55 | 1,438.20 |
| 31 May 2024 | Dividend | ₹ 32.00 /share | 31 May 2024 | 2,023.85 | 2,593.00 |
| 28 Jun 2024 | Annual General Meeting | NA | 28 Jun 2024 | 2,023.85 | 2,677.55 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 2,630.85 | 2,644.65 |
| 07 Nov 2024 | Dividend | ₹ 12.00 /share | 07 Nov 2024 | 2,644.65 | 2,632.20 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 2,077.20 | 1,998.80 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 2,928.60 | 2,721.25 |
| 30 May 2025 | Dividend | ₹ 42.00 /share | 30 May 2025 | 2,721.25 | 3,263.40 |
| 27 Jun 2025 | Annual General Meeting | NA | 27 Jun 2025 | 2,721.25 | 3,301.90 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 3,262.85 | 3,158.15 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,758.10 | 2,661.50 |
Announcements
Disclosure Under Regulation 30
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-AcquisitionNov 06, 2025
Nov 06, 2025Results Ended Quater September 2025Nov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Nov 06, 2025Board Meeting Outcome for OutcomeNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 29, 2025
Oct 29, 2025Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter & Half Year Ended 30Th September 2025.Oct 27, 2025
Oct 27, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 25, 2025
Sep 25, 2025Disclosure Under Regulation 30Sep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 25, 2025
Aug 25, 2025Disclosure Under Regulation 30Aug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Disclosure Under Regulation 30Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2025
Aug 04, 2025Rumour verification - Regulation 30(11)Aug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 02, 2025
Aug 02, 2025Clarification sought from GlaxoSmithKline Pharmaceuticals LtdAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 01, 2025
Aug 01, 2025Board Meeting Outcome for Outcome Of MeetingAug 01, 2025
Aug 01, 2025Quarter Ended 30Th June 2025Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Jul 09, 2025Board Meeting Intimation for Board Meeting Intimation
Jul 04, 2025
Jul 04, 2025Outcome Of AGMJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Disclosure Under Regulation 30Jun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Analyst MeetJun 20, 2025
Jun 20, 2025Disclosure Under Regulation 30Jun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025Letter To Shareholders For Annual Report LinkJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 05, 2025
Jun 05, 2025100Th Annual General Meeting On 27Th June 2025Jun 03, 2025
Jun 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 03, 2025
Jun 03, 2025Reg. 34 (1) Annual Report.Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 02, 2025
Jun 02, 2025Disclosure Under Regulation 30May 16, 2025
May 16, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Mutual Fund Holdings
Bajaj Finserv Flexi Cap Fund Direct-Growth 
SBI Quant Fund Direct-Growth 
Axis Quant Fund Direct-Growth 
DSP Quant Fund Direct - Growth 
Taurus Ethical Fund Direct-Growth 
360 ONE Quant Fund Direct - Growth 
Baroda BNP Paribas Midcap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Samco Dynamic Asset Allocation Fund Direct - Growth 
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth 
Sundaram Multi-Factor Fund Direct-Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
Motilal Oswal Nifty Midcap 150 Index Fund Direct - Growth 
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth 
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct - Growth 
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth 
ICICI Prudential Nifty Midcap 150 Index Fund Direct - Growth 
Kotak Nifty Midcap 150 Momentum 50 Index Fund Direct-Growth 
UTI Nifty Midcap 150 Quality 50 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 35.33
ATR(14)
Less Volatile 57.90
STOCH(9,6)
Oversold 18.07
STOCH RSI(14)
Neutral 47.45
MACD(12,26)
Bearish -3.99
ADX(14)
Strong Trend 35.80
UO(9)
Bearish 40.60
ROC(12)
Downtrend And Accelerating -6.48
WillR(14)
Oversold -81.89
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Website
Chairperson NameRenu S Karnad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
